2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-136623
    BW443C 88331-14-0 98%
    BW443C is a selective opioid receptor agonist. BW443C has antinociceptive effect.
    BW443C
  • HY-136653
    Ciramadol 63269-31-8 98%
    Ciramadol (WY 15705) is a potent and orally active analgesic agent with both narcotic agonist and UDP-glucuronyltransferase modulator properties. Ciramadol (WY 15705) can be used for postoperative pain research research.
    Ciramadol
  • HY-136654
    LPK-26 hydrochloride 492451-07-7 98%
    LPK-26 hydrochloride is a selective kappa-opioid receptor agonist with a Ki of 0.68 nM. LPK-26 exhibits potent antinociceptive effects with low physical dependence potential and can be utilized in relevant research.
    LPK-26 hydrochloride
  • HY-136678
    SB 258741 201038-58-6 98%
    SB 258741 is an efficient and highly selective 5-HT7 receptor (pKi = 8.
    SB 258741
  • HY-136693
    L-654284 98719-20-1 98%
    L-654284 is an α2-adrenergic receptor antagonist with significant selectivity. L-654284 competes with the binding of 3H-clonidine and 3H-rauwolscine in vitro and shows Ki values of 0.8 nM and 1.1 nM, respectively. L-654284 can block the protrusion effect of clonidine in isolated vas deferens in rats, with a pA2 value of 9.1. L-654284 exhibits remarkable selectivity for α2 and α1 adrenergic receptors, and exhibits a Ki of 110 nM in inhibiting 3H-prazosin binding. L-654284 can significantly increase the turnover rate of norepinephrine in rat cerebral cortex in vivo, showing α2-adrenergic receptor blocking activity in the central nervous system.
    L-654284
  • HY-136713
    Sirt1/2-IN-5 143034-06-4 98%
    Sirt1/2-IN-5 is a SIRT1/SIRT2 inhibitor with human SIRT1 IC50 0.3 μM and human SIRT2 IC50 values 1.2 μM and pIC50 5.82. Sirt1/2-IN-5 inhibits NAD+-dependent deacetylase activity of SIRT1 and SIRT2. Sirt1/2-IN-5 can be used for the research of cancer, neurodegenerative disease.
    Sirt1/2-IN-5
  • HY-136733
    Ac-DNLD-CHO 775289-20-8 98%
    Ac-DNLD-CHO (Ac-Asp-Asn-Leu-Asp-CHO) is a Caspase-3/7 inhibitor (IC50: 9.89, 245 nM respectively; Kiapp: 0.68, 55.7 nM respectively). Ac-DNLD-CHO can be used for research of caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases.
    Ac-DNLD-CHO
  • HY-136736
    β-Secretase Inhibitor II 263563-09-3 98%
    β-Secretase Inhibitor II is a β-Secretase inhibitor. β-Secretase Inhibitor II is a simple tripeptide aldehyde (IC50=700 nM for inhibition of total Aβ and IC50=2.5 μM for Aβ1–42). β-Secretase Inhibitor II can be used for the research of Alzheimer's disease.
    β-Secretase Inhibitor II
  • HY-136786
    RU-24213 hydrochloride 67383-44-2 98%
    RU-24213 hydrochloride is a selective D-2 dopamine receptor agonist. RU-24213 hydrochloride is also a KAPPA-opioid receptor antagonist. RU-24213 hydrochloride induces stereotyped behaviors.
    RU-24213 hydrochloride
  • HY-136804
    CypD-IN-29 1115335-95-9 98%
    CypD-IN-29 (compound 29) is an inhibitor of the Alzheimer's disease target CypD (KD=88.2 nM). CypD is a mitochondrial-specific cyclophilin that can bind to β-amyloid protein in brain mitochondria and promote the formation of mitochondrial permeability transition pore (mPTP).
    CypD-IN-29
  • HY-136805
    Kv1.5-IN-1 1469902-72-4 98%
    Kv1.5-IN-1 is a Kv1.5 channel inhibitor. Its target selectivity and pharmacodynamic effects were evaluated in an in vitro rat model. After the introduction of a methoxy group at the R5 position, Kv1.5-IN-1 showed inhibitory potency similar to that of the unsubstituted compound. Its IC50 value for hKv1.5 channels was 0.51 μM. Kv1.5-IN-1 exhibited a high degree of selectivity, nearly 2,600 times higher than compound Ik and 300 times higher than compound IId, indicating that it may be a safe inhibitor. Due to its good pharmacological behavior, Kv1.5-IN-1 deserves further pharmacodynamic and pharmacokinetic evaluation. These properties make Kv1.5-IN-1 a potential Kv1.5 channel inhibitor that may have application prospects in the treatment of related diseases.
    Kv1.5-IN-1
  • HY-136813
    Multitarget AD inhibitor-1 2205015-77-4 98%
    Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC50s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC50hBACE-1=41.60 μM), amyloid β aggregation (IC50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research.
    Multitarget AD inhibitor-1
  • HY-136842
    Oxetorone fumarate 34522-46-8 98%
    Oxetorone fumarate is a non-selective, orally active serotonin antagonist. Oxetorone fumarate is an antimigraine agent.
    Oxetorone fumarate
  • HY-136844
    LY-300168 143692-18-6 98%
    LY 300168 (GYKI 53655) is a non-competitive, blood-brain-barrier permeable AMPA receptor antagonist. LY 300168 attenuates hippocampal injury. LY 300168 blocks the sound-induced clonic and tonic convulsions.
    LY-300168
  • HY-136860
    (R)-Venlafaxine 93413-46-8 98%
    (R)-Venlafaxine is the R-enantiomer of venlafaxine (HY-B0196), an orally active and potent dual inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake. (R)-Venlafaxine can be utilized in antidepressant research.
    (R)-Venlafaxine
  • HY-136878
    LSD1-IN-10 1235864-15-9 98%
    LSD1-IN-10 is a LSD1/MAO inhibitor with LSD1 IC50 of 5 nM, MAO-A IC50 of 16 μM, and MAO-B IC50 of 7.4 μM. LSD1-IN-10 suppresses enzymatic activity of LSD1, MAO-A, and MAO-B. LSD1-IN-10 can be used for the research of cancer, alzheimer's disease, parkinson's disease, huntington's disease.
    LSD1-IN-10
  • HY-13694R
    Methionine (Standard) 348-67-4
    Methionine (Standard) is the analytical standard of Methionine. This product is intended for research and analytical applications. Methionine (MRX-1024; D-Methionine) is an effective chemoprotective agent which can also inhibit the neuronal activity through GABAA receptor activation.
    Methionine (Standard)
  • HY-137088
    Imiclopazine 7414-95-1 98%
    Imiclopazine is a phenothiazine derivative with with psychomotor stabilizing properties, antiaggressive and antiemetic effects.
    Imiclopazine
  • HY-137090
    BP 2-94 139191-80-3 98%
    BP 2-94 (BP 2.94) is an orally active and highly selective prodrug targeting the histamine H3 receptor. BP 2-94 exerts anti-inflammatory, analgesic and antinociceptive effects by inhibiting histamine release and modulating neurogenic inflammation. BP 2-94 is promising for research of asthma, migraines, and inflammatory pain-related disorders.
    BP 2-94
  • HY-137107
    Radafaxine 192374-14-4 98%
    Radafaxine ((S,S)-Hydroxybupropion) is an antidepressant. Radafaxine blocks dopamine transporters (DAT). Radafaxine is an active metabolite of Bupropion.
    Radafaxine
Cat. No. Product Name / Synonyms Application Reactivity